Uncertainty Looms as Trump’s Tariff Deal Leaves UK Pharma and Spirits in Waiting
Deals covering steel and technology sectors may already be sealed, but two major UK industries—pharmaceuticals and wine & spirits—remain caught in the crosshairs of Donald Trump’s evolving tariff strategy. Both sectors are anxiously awaiting confirmation of the promises the US president has made, as questions over scope, exemptions, and compliance with global trade rules continue to swirl.
Back in June, Washington pledged “significantly preferential” treatment for Britain’s pharmaceutical sector. However, several months later, this pledge has yet to translate into concrete policy. While the appearance of a top GlaxoSmithKline (GSK) executive at the state banquet in Windsor last night has been read by some as a signal that progress may be near, the details of what that “preferential treatment” actually means remain unclear.
At the heart of the debate is the question of whether the UK will secure a deeper discount on the current 10% blanket tariff and, crucially, which products are included under the exemption categories. The uncertainty mirrors similar challenges in Brussels, where EU leaders are still grappling with the fine print of the deal struck with the White House in late August.
Irish Prime Minister Simon Harris, speaking to The Guardian, admitted that “a big body of work” still lies ahead to determine exactly which products fall under the tariff categories. Trump’s agreement with the EU locked in a maximum 15% tariff on pharmaceuticals exported from the bloc. At the same time, the US committed to either a zero or near-zero tariff on “generic pharmaceuticals and their ingredients and chemical precursors.” Yet the precise scope of that exemption—especially whether medical devices are covered—remains unresolved.
“We don’t have that list of what the generics is or for medical devices,” Harris acknowledged, underlining the uncertainty facing European exporters.
The issue is further complicated by global trade rules. Trump’s decision to impose a 15% tariff on EU pharmaceutical exports appears to contravene a longstanding World Trade Organization (WTO) understanding that medicines should not face tariffs, primarily to ensure public health access and affordability. This move has already drawn scrutiny from legal experts and international observers.
Meanwhile, a second UK sector—wine and spirits—is also holding its breath. Both London and Brussels expect tariffs on these exports to revert to pre-Trump levels. Before the trade disputes of recent years, spirits entered the US at a zero tariff, while wine faced rates ranging between 0.5% and 1.8%. Industry stakeholders are pressing Washington to restore these conditions, arguing that prolonged higher tariffs would unfairly penalize producers and distort consumer prices.
The uncertainty comes at a sensitive moment for UK trade policy. With steel and tech already secured under the new arrangements, the government is keen to deliver a win for the life sciences and alcohol industries, two areas where Britain holds considerable export strengths. Yet without clarity from Washington, both sectors remain in limbo.
For now, industry leaders, EU negotiators, and UK officials alike will be watching closely for Trump’s next move. The question is no longer whether tariffs will be imposed—they already are—but rather who will bear the heaviest costs and who might secure exemptions in the fine print. Until then, the UK’s pharmaceutical and spirits sectors are left waiting, uncertain whether promises of preferential treatment will truly materialize or remain political talking points.
